Bioceres Crop Solutions Corp Stock Price, News & Analysis

Bioceres Crop Solutions (NASDAQ: BIOX) will host its fiscal first quarter 2026 earnings conference call on Thursday, November 13, 2025 at 8:30 a.m. ET to discuss results for the quarter ended September 30, 2025. A press release with results will be issued prior to the call.

Bioceres Chairman & CEO Federico Trucco and Head of Investor Relations Paula Savanti will host the call, which includes a presentation available via webcast and an investor relations page. Replay will be available through November 20, 2025.

Bioceres Crop Solutions (NASDAQ: BIOX) has formed a strategic partnership with the Colorado Wheat Research Foundation (CWRF) to develop and commercialize HB4® wheat in the United States. Through this collaboration, CWRF will receive exclusive, sublicensable rights to the HB4® trait in the U.S. and serve as Trait Manager.

The partnership aims to create a next-generation wheat production system combining climate resilience with sustainable weed management. The companies will jointly develop new broad-spectrum herbicide formulations specifically for HB4® wheat, integrated with Bioceres' biological solutions. Bioceres will maintain leadership of regulatory activities while ensuring alignment with U.S. Wheat Industry Principles for Biotechnology Commercialization.

The HB4® trait will be available through an open licensing model to all interested public and private wheat breeding programs in the U.S.

Bioceres Crop Solutions (NASDAQ: BIOX) reported challenging financial results for Q4 and FY2025. Total revenues declined to $74.7 million in Q4 (-40% YoY) and $335.3 million for FY25 (-28% YoY), primarily due to weaker demand in Argentina and lower HB4-related sales.

The company reported a Q4 net loss of $48.0 million and FY25 net loss of $55.2 million. Despite profitability challenges, net cash flow from operations improved by 27% YoY to $53.0 million in FY25. The company maintained a relatively stable full-year gross margin at 39%, supported by higher-value proprietary products.

In response, management is implementing cost-cutting measures, targeting 10-12% operating expense savings and reducing CAPEX and R&D investment rates by 50% to 2.5-3% of sales for FY26 and FY27.

Bioceres Crop Solutions (NASDAQ: BIOX), a company focused on agricultural ecosystem regeneration and climate-resilient crop solutions, has scheduled its fiscal fourth quarter and full year 2025 financial results conference call for Tuesday, September 9, 2025, at 8:30 a.m. ET.

The conference call will be hosted by CEO Federico Trucco and Head of IR Paula Savanti, featuring a presentation and Q&A session. Financial results will be released before the call, with presentation materials available through the company's investor relations website. A replay will be accessible until September 16, 2025.

Bioceres Crop Solutions (NASDAQ: BIOX) announced significant changes to its Board of Directors effective June 24, 2025. Noah Kolatch, Principal at Jasper Lake LLC, and Scott Crocco, former CFO of Air Products & Chemicals, will join the board. Gloria Montaron Estrada and Keith McGovern will step down from their director positions. Additionally, CFO Enrique Lopez Lecube will rotate off the board, to be replaced by CCO Milen Marinov. These changes coincide with amendments to note purchase agreements with various investors, including Jasper Lake Ventures One LLC and Solel-Bioceres SPV, L.P. The company highlighted the incoming directors' expertise in investment, finance, and operations, while acknowledging the contributions of departing board members in areas such as legal strategy and operational excellence.

Bioceres Crop Solutions (NASDAQ: BIOX) reported its fiscal Q3 2025 results with total revenues of $60.6 million, down 28% from $84.0 million in 3Q24. The company posted a net loss of $1.6 million and Adjusted EBITDA of $9.0 million. Despite lower revenues, Bioceres achieved significant improvement in cash flow management, with operating cash flow reaching $23.3 million, a $40.7 million improvement year-over-year. The quarter was marked by the EPA registration of Rinotec™, their new biological insecticide and nematicide platform. The company's strategic shift in seed business and cost optimization efforts are showing early benefits, with reduced operating expenses and streamlined operations. Segment-wise, Crop Protection revenue declined 19% to $38.0 million, Seed and Integrated Products grew 26% to $10.9 million, and Crop Nutrition fell 59% to $11.8 million.

Bioceres Crop Solutions (NASDAQ: BIOX), a company specializing in agricultural productivity solutions and ecosystem regeneration, has scheduled its fiscal third quarter 2025 financial results conference call for Wednesday, May 21, 2025, at 8:30 a.m. ET. The company will release its financial results for the quarter ended March 31, 2025, before the call.

The conference call will feature key executives including CEO Federico Trucco, CFO Enrique Lopez Lecube, CCO Milen Marinov, and Head of IR Paula Savanti. A presentation will accompany the webcast, accessible through the company's investor relations website. The call replay will be available until June 4, 2025.

Bioceres Crop Solutions (NASDAQ: BIOX) has received EPA federal registration for Rinotec, its innovative insecticide and nematicide platform. The product, which is exempt from residue tolerance requirements due to its negligible risk to human health and non-target organisms, has already secured approval for commercialization in Brazil.

The Rinotec platform features a unique metabolite-based approach to biologicals that enables significant dose reductions while maintaining the efficiency of synthetic chemical pesticides. This makes it suitable for both row and specialty crops. With registrations in both the U.S. and Brazilian markets, BIOX is now positioned to advance its regulatory and commercial strategies in two of the world's largest agricultural economies.

Bioceres Crop Solutions (NASDAQ: BIOX) has received a Notice of Allowance from the USPTO for its first event-specific patent covering HB4 Wheat, securing protection until 2042. This is the first of four potential patents for HB4 Wheat in the United States.

HB4 wheat technology offers improved drought tolerance and enhanced weed management compared to conventional wheat. The technology has already received USDA approval for cultivation and FDA approval for food and feed use in the U.S., which is the fourth largest wheat producer with nearly 40 million acres harvested in the most recent marketing year.

The company will follow the U.S. Wheat Associates' biotechnology commercialization principles, including securing regulatory approvals in major export markets, establishing tolerance thresholds, providing trait detection tests, and implementing product stewardship. The commercial rollout will utilize a broad licensing approach.